These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 36077477)

  • 1. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy.
    Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ
    JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
    Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
    Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
    Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
    Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
    J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).
    Wang Q; Liu H; Shen Y; Shen L; Li J; Feng W
    J Ovarian Res; 2024 Jul; 17(1):145. PubMed ID: 38997720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
    N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
    Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
    J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
    Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
    Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review.
    van Stein RM; Aalbers AGJ; Sonke GS; van Driel WJ
    JAMA Oncol; 2021 Aug; 7(8):1231-1238. PubMed ID: 33956063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.